Chronic Liver Disease Thrombopoietin Treatment Study 2021-2023

From January 2021 to October 2023, a retrospective study analyzed 259 patients with chronic liver disease-associated thrombocytopenia treated with recombinant human thrombopoietin at Henan Provincial People’s Hospital. The data includes patient outcomes grouped by concomitant infection status, with primary endpoints of response rate and time to response, and secondary endpoints like platelet transfusion requirements and recovery differences.

Use Cases

• Analyze the relationship between Child–Pugh C classification and response rate to rhTPO treatment.
• Compare platelet transfusion rates between concomitant infection and non-concomitant infection patient groups.
• Model the time to response for patients with cirrhosis as an independent factor.
• Investigate platelet count trajectories from Day 3 to 28 days post-discontinuation across infection status groups.

Strengths

• Study includes 259 patient records from a defined hospital setting.
• Data covers a specific time range from January 2021 to October 2023.
• Analysis uses propensity score matching on 132 patients to adjust for baseline confounders.

Limitations

• Dataset is small at 14.5 KB, derived from a single hospital study, limiting generalizability.
• Data is observational and retrospective, which may introduce selection bias.
• Specific columnar data structure and sample data are unavailable for direct analysis.

Provenance

Source

figshare, authored by Xun Wei.

Collection Method

Retrospective study of patient medical records.

Time Range

January 2021 to October 2023.

Freshness

Data last updated on 2026-03-23, though the study period ended in October 2023.

Geography

Henan Provincial People’s Hospital, China.